Oxford Cannabinoid CEO Reflects on 2023 as the Company Transitioned into Clinical Trials #octp

StockBox

10.8K subscribers

ShareSubscribe

Clarissa reflects on her first year as CEO, expressing pride in leading OCT's team and interacting with shareholders and stakeholders. Highlights include OCT's transition from a pre-clinical to a clinical company, marked by their first Phase 1 trial approval and completion. The company has made progress in its lead compound for CIPN and is venturing into oncology with potential immunotherapy treatments for solid tumors. Looking Ahead to 2024 Clarissa anticipates more operational achievements in 2024, focusing on advancing current programs. Hinting at exciting developments to be revealed in the upcoming year, maintaining a strong commitment to operational delivery and strategic growth at OCT.